[Interferon alpha 2ß, partial keratectomy and amniotic membrane transplant for the treatment of a recurrent conjunctival squamous carcinoma]. / Interferón alfa 2-ß, queratectomía parcial y trasplante de membrana amniótica para el tratamiento de un carcinoma escamoso conjuntival recidivante.

CASE REPORT: An 80-year-old woman diagnosed with a recurrent squamous conjuctival carcinoma treated with surgical excision of the lesion, zonal reconstruction and topical Interferon alpha 2-ß. DISCUSSION: Squamous conjunctival carcinoma is the most frequent neoplasm of the ocular surface. Surgical removal of the lesion is the traditional treatment, but this technique has a high recurrence rate. Interferons are glycoproteins that trigger intracellular pathways with antiviral and antitumoral properties. Recent studies have proven their activity against conjunctival carcinoma.

Interferón alfa 2-b, queratectomía parcial y trasplante de membrana amniótica para el tratamiento de un carcinoma escamoso conjuntival recidivante / Interferon alpha 2b, partial keratectomy and amniotic membrane transplant for the treatment of a recurrent conjunctival squamous carcinoma

Caso clínico: Mujer de 80 años de edad diagnosticada de carcinoma escamoso conjuntival recidivante tratado con escisión quirúrgica de la lesión, reconstrucción zonal e interferónalfa 2-b tópico. Discusión: La neoplasia escamosa de la conjuntiva y córnea es el tumor más frecuente dela superficie ocular. La cirugía mediante resección de la lesión es el método tradicional de tratamiento de estos tumores, pero presenta un elevado índice de recurrencias. La inmunoterapia es una alternativa actual para estos tumores. Los interferones son glicoproteínasque actúan activando una cascada de eventos intracelulares que confieren una actividad antivirales y antitumoral. Su actividad frente a las neoplasias epiteliales de la superficieocular se ha demostrado en los últimos años(AU)

Case report: An 80-year-old woman diagnosed with a recurrent squamous conjuctival carcinoma treated with surgical excision of the lesion, zonal reconstruction and topical Interferonalpha 2-b. Discussion: Squamous conjunctival carcinoma is the most frequent neoplasm of the ocularsurface. Surgical removal of the lesion is the traditional treatment, but this technique has a high recurrence rate. Interferons are glycoproteins that trigger intracellular path ways with antiviral and antitumoral properties. Recent studies have proven their activity againstconjunctival carcinoma(AU)

Fixed-dose combination of 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution for inflammation after cataract surgery: a randomized, comparative, active treatment-controlled trial.

PURPOSE: To assess the efficacy, tolerance, and ocular tolerability of a fixed-dose combination of 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution compared with 0.1% diclofenac (Voltaren) and 0.3% tobramycin (Tobrex) in patients undergoing cataract extraction by either nuclear expression (extracapsular) or ultrasound-assisted aspiration (phacoemulsification) with intraocular lens implantation. METHODS: Eighty-eight patients undergoing cataract extraction with intraocular lens implantation participated in a randomized, parallel, observer-masked trial, in which the clinical usefulness of a fixed-dose combination of 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution, two eyedrops every 6 hours (n = 44) was compared with Voltaren and Tobrex, one drop of each every 6 hours (n = 44) in a 22-day course. Efficacy was assessed from changes of the sum of anterior chamber cell count plus flare, conjunctival hyperemia and edema, and ciliary congestion, by means of slit lamp biomicroscopy on days 1, 7, 14, and 21. Tolerance and ocular tolerability were assessed by recording intraocular pressure (IOP), side effects, and the patient's and investigator's opinions. RESULTS: Anterior chamber cell count plus flare showed no differences in the two treatment groups at any evaluation point. The study treatment was associated with a significantly higher score for conjunctival edema on day 1 (p = 0.015), conjuncitval hyperemia on day 14 (p = 0.009) and anterior chamber cell count on day 21 (p = 0.04), but these differences had no clinical relevance. No side effects related to the study treatment were recorded. CONCLUSIONS: Efficacy, tolerance, and ocular tolerability of a fixed-dose combination of 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution were comparable to Voltaren plus Tobrex for the control of anterior chamber inflammation after cataract surgery, with the advantage that both active principles are supplied in a single container.

Storage, surgery, outcome, complications, and new developments in corneal and conjunctival grafts.

This review covers last year's literature on corneal, limbal, and conjunctival transplantation including tissue storage and eye banking. In this area, the main themes were related to a better evaluation of tissue viability and the exclusion of disease transmission. An analysis of the changing indications for penetrating keratoplasty shows the differences between American and European series. Most efforts in relation to surgical techniques are oriented toward obtaining better refractive results, whereas the study of large series sheds new light on the risk factors for graft failure and other complications. Limbal transplants have acquired the status of a new field in the surgical treatment of ocular surface disease, particularly in relation to corneal stem cell deficiencies.